TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05710770

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immunoadsorption
Description: IA is a well-established, safe interventional therapy broadly applied for different indications. Medical complaints of the TheraSorb Ig apheresis system are rare and none led to a long-term impairment of the patient's health. In most treatments, the patients do not report any side effects. The Ig omni adsorbers specifically remove antibodies. Other components of the blood, except for an unspecific loss of plasma during the treatment, are not removed. Main adverse effects can occur due to the necessity of a Shaldon catheter and include accidental puncture of carotid artery. The procedure is performed under sonographic control and a chest-x-ray is performed afterwards to ensure integrity of lungs.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Immunoadsorption
Description: IA is a well-established, safe interventional therapy broadly applied for different indications. Medical complaints of the TheraSorb Ig apheresis system are rare and none led to a long-term impairment of the patient's health. In most treatments, the patients do not report any side effects. The Ig omni adsorbers specifically remove antibodies. Other components of the blood, except for an unspecific loss of plasma during the treatment, are not removed. Main adverse effects can occur due to the necessity of a Shaldon catheter and include accidental puncture of carotid artery. The procedure is performed under sonographic control and a chest-x-ray is performed afterwards to ensure integrity of lungs.
Study: NCT05474469

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic breathing exercises
Description: 12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing exercises
Description: 12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal muscle strengthening exercises
Description: 12 treatment sessions for 4 weeks period, which consisted of 03 treatment sessions per week.
Study: NCT05849896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acquisition of HD sEMG signals using the WPM-SEMG device
Description: The WPM-SEMG-V2 device will be placed over the muscle of the participant to be investigated. A reference electrode over a bone close to the muscle of investigation will be applied. A sensor combing an accelerometer, gyroscope and magnetometer integrated in the WPM-SEMG-V2 device will be also used for the acquisition of body movement measures. An additional component for trapezoidal force measurement will be used during the acquisition in static contractions to measure the force. The participant will be instructed by the investigator how to execute the static or the dynamic exercises. Visual feedback will help the subject to track the trajectory.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acquisition of HD sEMG signals using the WPM-SEMG device
Description: The WPM-SEMG-V2 device will be placed over the muscle of the participant to be investigated. A reference electrode over a bone close to the muscle of investigation will be applied. A sensor combing an accelerometer, gyroscope and magnetometer integrated in the WPM-SEMG-V2 device will be also used for the acquisition of body movement measures. An additional component for trapezoidal force measurement will be used during the acquisition in static contractions to measure the force. The participant will be instructed by the investigator how to execute the static or the dynamic exercises. Visual feedback will help the subject to track the trajectory.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acquisition of HD sEMG signals using the WPM-SEMG device
Description: The WPM-SEMG-V2 device will be placed over the muscle of the participant to be investigated. A reference electrode over a bone close to the muscle of investigation will be applied. A sensor combing an accelerometer, gyroscope and magnetometer integrated in the WPM-SEMG-V2 device will be also used for the acquisition of body movement measures. An additional component for trapezoidal force measurement will be used during the acquisition in static contractions to measure the force. The participant will be instructed by the investigator how to execute the static or the dynamic exercises. Visual feedback will help the subject to track the trajectory.
Study: NCT05276765

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cad/cam socket sealing abutment
Description: Anatomically formed healing abutments that can solve many of the problems inherent to immediate posterior implant placement and to optimize the conditioning of supra implant tissue architecture enhancing the emergence profile of the final implant restoration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard healing abutment
Description: Standard healing abutment will be inserted after removal of cover screw after immediate implant insertion and then a muco-periosteal flap will be reflected for the primary closure of the socket and sutured around the standard healing abutment.
Study: NCT05559073

Intervention type: PROCEDURE
Intervention: Radiofrequency ablation
Description: pulmonary vein isolation using radiofrequency ablation.

Intervention type: PROCEDURE
Intervention: Radiofrequency ablation
Description: pulmonary vein isolation using radiofrequency ablation.
Study: NCT05211609

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Plasmatic 3-O-Methyldopa dosage
Description: Plasmatic 3-O-Methyldopa dosage
Study: NCT06288633

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ganglionated plexi ablation
Description: Through access in the femoral vein, a mapping or ablation-mapping catheter is inserted into the right atrium, and a three-dimensional reconstruction of the right atrium is performed using an electroanatomic mapping system. The inferior and superior vena cava, the coronary sinus are indicated.~Then a transeptal puncture is performed using a transeptal introducer and a needle for transeptal puncture under fluoroscopic control. A three-dimensional reconstruction of the left atrium is performed using an electroanatomic mapping system.~During or immediately after the creation of three-dimensional maps of both atria, areas of the typical concentration of ganglion plexuses (GP) are ablated using radiofrequency applications (30-50 Watts, 10-40 s each point). Ablated points are annotated on the three-dimensional map. GPs ablation zones are about 0.5 x 1.0 cm in size.
Study: NCT05340543

Intervention type: PROCEDURE
Intervention: Confocal optical coherence tomography - OCTAVE
Description: An ex vivo examination of cutaneous resection with the OCTAV® prototype integrating the dermoscope function

Intervention type: PROCEDURE
Intervention: Confocal optical coherence tomography - OCTAVE
Description: An ex vivo examination of cutaneous resection with the OCTAV® prototype integrating the dermoscope function

Intervention type: PROCEDURE
Intervention: Confocal optical coherence tomography - OCTAVE
Description: An ex vivo examination of cutaneous resection with the OCTAV® prototype integrating the dermoscope function
Study: NCT06151496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-Agonist
Description: The maternal systolic blood pressure was consistently maintained above 80% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: α-adrenergic receptor agonist
Description: The maternal systolic blood pressure was consistently maintained above 90% of the preoperative baseline value from the initiation of spinal anesthesia until fetal delivery.
Study: NCT05199168

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraoperative nerve monitoring
Description: Intraoperative bilateral recurrent laryngeal nerve monitoring was utilized during dissection of right and left recurrent laryngeal nerve lymph nodes.
Study: NCT06288633

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Electrophysiological study
Description: Through access in the femoral vein, a diagnostic catheter is inserted in the area of the coronary sinus under fluoroscopic control. The effective refractory period (ERP) of the atria will be measured according to the method adopted in clinical practice, namely: using a ten-pole diagnostic electrode installed in the coronary sinus, a series of eight electrical pulses with the same amplitude and frequency is applied to the atrial myocardium. Then the ninth pulse is applied with a gradual decrease in the time interval until the absence of an atrial myocardium response to the pulse is registered. The cycle of an additional, ninth pulse, in which the atrial myocardium did not respond to an electrical impulse, is considered an atrial ERP.
Study: NCT05433727

Intervention type: DIAGNOSTIC_TEST
Intervention: videodermoscopy, lesional capillaroscopy
Description: videodermoscopy and lesional capillaroscopy will be performed under different magnification levels to the skin lesions and data will be recorded.

Intervention type: DIAGNOSTIC_TEST
Intervention: videodermoscopy, lesional capillaroscopy
Description: videodermoscopy and lesional capillaroscopy will be performed under different magnification levels to the skin lesions and data will be recorded.
Study: NCT05869461

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KP Specific Wellness Sessions
Description: The sessions will include content on yoga, nutrition, legal issues, medical information, and community resources from the original Chetana intervention (further described below). They will also include expanded content informed by our previous studies and focus group discussions with MSM and TGW that addresses the needs for sessions on mental health, financial literacy, substance use, legal rights for key populations and coping skills for interacting with the legal system, and community resources for MSM and TGW. Sessions will include specifically tailored content related to the needs of MSM or TGW.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Navigation
Description: Participants will be assigned to a peer navigator (PN) who will be their principal point of contact for the intervention. Within a week, the navigator will set up an initial introductory meeting, either in person or via video chat. This will serve as the first monthly check-in to monitor a participant's progress. During these in-person digital meetings, the navigator will work with a participant to identify their unique barriers that currently affect engagement in care and train participants to identify and break down solutions into manageable steps. Special attention will be paid to barriers associated with intersectional stigma and PNs will draw on their own experiences as members of stigmatized groups in identifying and brainstorming successful coping strategies. While this is not a structural intervention, PNs will work with their clients to develop ways of coping with structural barriers, including transportation and referrals to social services.
Study: NCT06306586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Treatment for Adolescents With Eating Disorders
Description: The main aim of the digital treatment is to reduce symptoms of eating disorders and increase life-coping skills. The digital treatment aims to help adolescents with eating disorders to:~* Gain knowledge about the symptoms of eating disorders and the consequences it has on everyday life.~* Be motivated to carry out the treatment.~* Gain knowledge of and skills in regulating food and activity in a more balanced way.~* Gain knowledge of and skills in managing emotions.~* Get tools to develop a better self-esteem.~* Gain awareness of the function of the eating disorder.~* Gain skills in coping with social challenges.~* Get a more realistic image of their bodies and handle information from social media.
Study: NCT05549518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stabilization + Traditional Physical Therapy
Description: In addition to the traditional physical therapy training, core stabilization exercises will be applied 3 days a week for 6 weeks, and 20 minutes in each session under the supervision of a physiotherapist. Core stabilization exercises; will gradually progress from easy exercises to difficult ones. Exercises will be performed in supine, hook position, sitting position, on stable and mobile surfaces. Exercises will progress from 1 set to 3 sets, from 7 to 10 reps, contractions from 3 seconds to 10 seconds. All exercises will be performed with breathing control.~The exercises will be progressed by gradually increasing them every week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy
Description: Traditional physical therapy training will be given for 40 minutes each session, 3 times a week for 6 weeks under the supervision of a physiotherapist. As a traditional physical therapy program, a rehabilitation program that increases mobility and daily living activities will be applied to patients.~* Joint range of motion exercises~* Stretching exercises~* Strengthening exercises~* Bobath-based neurophysiological approaches~* Task-oriented training~* 15 minutes of neuromuscular electrical stimulation (NMES) application
Study: NCT05059938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyFitnessPal user
Description: Patients will be counseled on how to use the MyFitnessPal application to help with the patient's weight loss goals. The physician will monitor the patient's weight, blood pressure, and waist circumference over up to a six month period with visits at 1, 3, and 6 months. Patients will be asked about the patient's use of the application at the end of the study.
Study: NCT05236959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: Following an initial interview session, patients are offered eight weekly group-based session, delivered via videoconferencing, and asked to engage in regular daily home practice of mindfulness meditation
Study: NCT05685420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herombopag
Description: Thrombopoietin receptor agonist
Study: NCT05236959

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Following an initial interview session, patients continue with their usual care
Study: NCT04639843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486 (5-azacitidine)
Description: CC-486 (5-azacitidine) with a dose of 300mg oral intake daily will be given on day 1 to day 10 for 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-486 (5-azacitidine)
Description: CC-486 (5-azacitidine) with a dose of 300mg oral intake daily will be given on day 1 to day 10 for 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Duvelisib by oral intake at escalating doses of 25, 50 and 75 mg/BID on days -14 to 14 of the 1st cycle then days 1-14 of Cycles 2-8 of each 21- day cycle (max 8 cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Duvelisib by oral intake at escalating doses of 25, 50 and 75 mg/BID on days -14 to 14 of the 1st cycle then days 1-14 of Cycles 2-8 of each 21- day cycle (max 8 cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin (12mg/m2) will be administered on days 1 and 8 of each cycle through a peripheral or central intravenous catheter for 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin (12mg/m2) will be administered on days 1 and 8 of each cycle through a peripheral or central intravenous catheter for 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin at 25 mg/ m2 by IV infusion on Day 1 of cycles 3-8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin at 25 mg/ m2 by IV infusion on Day 1 of cycles 3-8.
Study: NCT06530121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Toolbox trainings
Description: Training given with a single page material, lasting between 10-15 minutes, aimed at on-the-job application.
Study: NCT04505878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C is a first-line antioxidant that directly scavenges free radicals, inhibits reactive oxygen species (ROS) producing enzymes and recovers other cellular antioxidants
Study: NCT05041621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor augmented MDI therapy plus mobile application
Description: Participants will use the mobile application to calculate their basal dose and to calculate their meal bolus dose by entering their glucose value, carbs (if applicable), fat composition (high fat or not), and type and timing of postprandial exercises. Participants will receive their dosing parameters weekly upon adjustments made by the reinforcement learning algorithm. Participants will be contacted by telephone on Weeks 1, 3, 5, and 7 in case of any technical difficulties or questions.~All participants will be asked to complete the:~(i) Diabetes treatment satisfaction questionnaire (DTSQ) and hypoglycemia fear survey-II (HFS-II) at baseline, halfway through the intervention, and post-intervention.~(ii) mHealth usability questionnaire (MAUQ) at post-intervention.
Study: NCT05975138

Intervention type: PROCEDURE
Intervention: implant insertion
Description: a minimally invasive full-thickness flap will be raised in order to visualize the anatomy of the ridge. The vertical thickness of the supracrestal soft tissue will be measured and recorded. The preparation of the implant site will be performed with rotary burs and the bone quality will be recorded. An implant will be placed according to the manufacturer's recommendations. The length of the implant will be chosen in order to obtain a bicortical anchorage on the floor of the maxillary sinus

Intervention type: PROCEDURE
Intervention: implant insertion
Description: a minimally invasive full-thickness flap will be raised in order to visualize the anatomy of the ridge. The vertical thickness of the supracrestal soft tissue will be measured and recorded. The preparation of the implant site will be performed with rotary burs and the bone quality will be recorded. An implant will be placed according to the manufacturer's recommendations. The length of the implant will be chosen in order to obtain a bicortical anchorage on the floor of the maxillary sinus
Study: NCT05274061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerated, Intensive, Multi-Couple Cognitive Behavioral Couples Therapy
Description: AIM-CBCT consists of an accelerated, 2-day delivery of the first 7 sessions of CBCT for PTSD and is comprised of (a) psychoeducation about PTSD and relationship functioning; (b) instruction in conflict management skills; (c) instruction in effective communication skills with an emphasis on the identification and sharing of emotions to decrease emotional numbing and increase emotional intimacy; (d) discussion of the importance of approaching, rather than avoiding, difficult situations and identification of places, situations, people, and feelings that the couple has heretofore avoided as a result of PTSD; (e) instruction in identification of thoughts and related feelings that can maintain PTSD and relationship distress and strategies to increase cognitive flexibility, and (f) instruction in problem-solving skills to generate couple-level approach behaviors and guidance in how to select activities that double as opportunities to approach feared situations and engage in positive bonding.
Study: NCT05034614

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Papette brush collection
Description: Cervical cell brush that gathers collects cervical cells during Pap smear collection

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Spatula/cytology brush collection
Description: Combination of extended-tip spatula with endocervical brush that collects cervical cells during Pap smear collection
Study: NCT05280275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab Mafodotin-Blmf
Description: Blmf will be available as 100 mg/vial in single-use vial for reconstitution, supplied as lyophilized powder.~Blmf will be delivered as IV solution over at least 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered with subcutaneous injections. On days where Blmf is given together with daratumumab, daratumumab should be performed first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered per os.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered intravenously or per os.
Study: NCT05227209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEP-4199 CR
Description: SEP-4199 CR either 200 mg (one 200 mg tablet) or 400 mg (two 200 mg tablets) once daily
Study: NCT05545410

Intervention type: OTHER
Group type: OTHER
Intervention: MRI calibration
Description: Non-injected thoracic aorta MRI calibration
Study: NCT06401499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib 60mg
Description: investigator will compare effects of etoricoxib alone and in combination with pregabalin on pain relief in chronic low back pain participants
Study: NCT05152290

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study: NCT04142385

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo blood, urethral swab, penile skin cell, and anal swab collection

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Intervention: Medical Examination
Description: Undergo anal and penile clinical exam

Intervention type: PROCEDURE
Intervention: Physical Examination
Description: Undergo targeted physical exam

Intervention type: PROCEDURE
Intervention: Proctoscopy with Biopsy
Description: Undergo HRA

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05646420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: A blood sample of 15 ml will be collected for each patient.